The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Triplet maintenance (olaparib, pembrolizumab, and bevacizumab) in BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer: A multi-center, single-arm phase II study (OPEB-01).
 
Yoo Na Kim
No Relationships to Disclose
 
Boram Park
No Relationships to Disclose
 
Je-Gun Joung
No Relationships to Disclose
 
Jae-Weon Kim
No Relationships to Disclose
 
Byoung-Gie Kim
No Relationships to Disclose
 
Sang Wun Kim
No Relationships to Disclose
 
Hee Seung Kim
No Relationships to Disclose
 
Chel Hun Choi
No Relationships to Disclose
 
Myong Cheol Lim
Consulting or Advisory Role - AstraZeneca; Boryung; CKD Pharm; Genexine; GI Innovation; Hospicare; Takeda
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma; AstraZeneca (Inst); BeiGene (Inst); Cellid (Inst); CKD pharm (Inst); Clovis Oncology (Inst); Eisai (Inst); Genexine (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Incyte (Inst); Merck (Inst); MSD (Inst); OncoQuest (Inst); Pfizer (Inst); Roche (Inst)
 
Natalie Yl Ngoi
Research Funding - AstraZeneca; Pfizer
 
David Shao Peng Tan
Stock and Other Ownership Interests - Asian Microbiome Library
Consulting or Advisory Role - AstraZeneca; Eisai; EMD Serono; Genmab; GlaxoSmithKline; Merck; MSD; Roche
Research Funding - AstraZeneca; Bayer; BMSi; Eisai; Karyopharm Therapeutics; MSD; National Medical Research Council/Ministry of Health Singapore
 
Jung-Yun Lee
Research Funding - AstraZeneca; BeiGene; BerGenBio; Clovis Oncology; ImmunoGen; Janssen; Merck; MSD; Novartis; Roche; Seagen; Synthon; Takeda